Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pitts

Showing results (231-240 of 268) with videos related to

Pageof 27
Sort By:
BMC Cancer|February 7, 2018
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPeter J Klauck, Stacey M Bagby, Anna Capasso, et al.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Cancer Research Communications|September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic MicroenvironmentJesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Endocrine-Related Cancer|January 27, 2018
Development of new preclinical models to advance adrenocortical carcinoma researchKatja Kiseljak-Vassiliades, Yu Zhang, Stacey M Bagby, et al.
Cancers|April 27, 2024
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid TumorsS Lindsey Davis, Wells A Messersmith, W Thomas Purcell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Immunity|August 17, 2022
Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucomaMilica A Margeta, Zhuoran Yin, Charlotte Madore, et al.
Plos One|April 10, 2024
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, et al.
Pageof 27

Showing results (231-240 of 268) with videos related to

Sort By:
Pageof 27
BMC Cancer|February 7, 2018
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPeter J Klauck, Stacey M Bagby, Anna Capasso, et al.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Cancer Research Communications|September 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic MicroenvironmentJesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Endocrine-Related Cancer|January 27, 2018
Development of new preclinical models to advance adrenocortical carcinoma researchKatja Kiseljak-Vassiliades, Yu Zhang, Stacey M Bagby, et al.
Cancers|April 27, 2024
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid TumorsS Lindsey Davis, Wells A Messersmith, W Thomas Purcell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Immunity|August 17, 2022
Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucomaMilica A Margeta, Zhuoran Yin, Charlotte Madore, et al.
Plos One|April 10, 2024
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, et al.
Pageof 27